Post-marketing surveillance of long-term administration of Inovelon tablets in patients with Lennox-Gastaut syndrome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080222123

Enrollment

300

Registered

2013-06-21

Start date

2013-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lennox-Gastaut syndrome

Interventions

investigational material(s) Generic name etc : Inovelon INN of investigational material : Rufinamide Therapeutic category code : 113 Antiepileptics Dosage and Administration for Investigational materi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with Lennox-Gastaut syndrome and administrated Inovelon

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
safety efficacy Frequency of attacks Whole improvement level	—

Secondary

Measure	Time frame
other None	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026